Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.

被引：0
|
作者：
Goujon, Morgan [1 ]
Anota, Amelie [2 ,3 ]
Charton, Frontczak Alexandre [4 ]
Charton, Emilie [5 ,6 ]
Maurina, Tristan [1 ]
Almotlak, Hamadi [1 ]
Nguyen, Thierry [1 ]
Fabien, Calcagno [1 ]
Stein, Ulrich [1 ]
Mouillet, Guillaume [7 ]
Thiery-Vuillemin, Antoine [8 ]
机构：
[1] Univ Hosp, Dept Med Oncol, Besancon, France
[2] Univ Hosp Besancon, Qual Life Oncol Clin Res Platform, Besancon, France
[3] Univ Hosp Besancon, Methodol & Qual Life Oncol, INSERM UMR 1098, Besancon, France
[4] Univ Hosp, Dept Urol, Besancon, France
[5] Univ Hosp Besancon, Methodol & Qual Life Unit, Dept Oncol, INSERM UMR 1098, Besancon, France
[6] French Natl Platform Qual Life & Canc, Besancon, France
[7] Univ Hosp, Dept Med Oncol, Methodol & Qual Life Unit Oncol, INSERM UMR 1098, Besancon, France
[8] Univ Hosp, Dept Med Oncol, INSERM UMR 1098, Besancon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.54
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
54
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Prognostic factors for patients with metastatic castrate-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy.
    Charnley, Natalie
    Birtle, Alison J.
    Swindell, Ric
    Parikh, Omi
    Wise, Marcus
    Kumar, Varadarajan
    Danwata, Falalu Dahiru
    Thompson, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] HEALTH-RELATED QUALITY OF LIFE AND TREATMENT SATISFACTION AMONG PATIENTS RECEIVING NOVEL ANTI-ANDROGEN THERAPIES FOR THE TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
    Dearden, L.
    Shalet, N.
    Artenie, C.
    Mills, A.
    Gater, A.
    Grant, L.
    Jackson, C.
    VALUE IN HEALTH, 2015, 18 (07) : A472 - A472
  • [23] Health-related quality of life (HRQoL) and pain in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
    Sicotte, Hugues
    Kalari, Krishna R.
    Qin, Sisi
    Dehm, Scott M.
    Bhargava, Vipul
    Gormley, Michael
    Tan, Winston
    Sinnwell, Jason P.
    Hillman, David W.
    Li, Ying
    Vedell, Peter T.
    Carlson, Rachel E.
    Bryce, Alan H.
    Jimenez, Raphael E.
    Weinshilboum, Richard M.
    Kohli, Manish
    Wang, Liewei
    MOLECULAR CANCER RESEARCH, 2022, 20 (12) : 1739 - 1750
  • [25] Development of a predictive model of PSA response to a switch from prednisone to dexamethasone in metastatic castrate-resistant prostate cancer patients biochemically progressing on abiraterone
    Barua, Reeta
    Phillips, Cameron
    Arciero, Vanessa Sarah
    Zhang, Liying
    Rahmadian, Amanda
    Delos Santos, Seanthel
    Parshad, Shruti
    Emmenegger, Urban
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Small, Eric Jay
    Lance, Raymond S.
    Redfern, Charles H.
    Millard, Frederick E.
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Dawson, Nancy Ann
    McCoy, Candice
    Stubbs, Andrew
    DeVries, Todd
    dela Rosa, Corazon P.
    Sheikh, Nadeem A.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Nutritional Status and Health-Related Quality of Life in Men with Advanced Castrate-Resistant Prostate Cancer
    Cavka, Luka
    Perme, Maja Pohar
    Zakotnik, Branko
    Kozjek, Nada Rotovnik
    Seruga, Bostjan
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2022, 74 (02): : 472 - 481
  • [28] AZD8186, a potent and selective inhibitor of PI3Kb/d, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    de Bono, J. S.
    Hansen, A.
    Choudhury, A. D.
    Cook, N.
    Heath, E. I.
    Higano, C.
    Linch, M.
    Martin-Liberal, J.
    Rathkopf, D. E.
    Wisinski, K. B.
    Barry, S.
    de Bruin, E.
    Brugger, W.
    Colebrook, S.
    Klinowska, T.
    Moschetta, M.
    Mortimer, P. G. S.
    Siu, L. L.
    Shapiro, G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).
    Khalaf, Daniel
    Sunderland, Katherine
    Eigl, Bernhard J.
    Finch, Daygen L.
    Oja, Conrad D.
    Vergidis, Joanna
    Parimi, Sunil
    Zulfiqar, Muhammad
    Gleave, Martin
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).
    George, Daniel J.
    Heath, Elisabeth I.
    Sartor, A. Oliver
    Sonpavde, Guru
    Berry, William R.
    Healy, Patrick
    Winters, Carolyn
    Riggan, Colleen
    Anand, Monika
    Kephart, Julie
    Milowsky, Matthew I.
    Fleming, Mark T.
    Balaji, K. C.
    Zhang, Tian
    Bitting, Rhonda L.
    Harrison, Michael Roger
    McNamara, Megan Ann
    Freedman, Jennifer A.
    Halabi, Susan
    Armstrong, Andrew J.
    Bruner, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
12345